Crohn Disease Clinical Trials in Chicago, Illinois

4 studies are recruiting for crohn disease in Chicago, Illinois right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

  1. Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO

    This phase Ib trial studies the side effects of nivolumab and to see how well it works alone and in combination with other treatments, such as ipilimumab, cabozantinib, platinum containing therapy, and fluoropyrimidine, in treating patients with autoimmune disorders and cancer that has spread from …

    Stage
    Phase 1
    Ages
    18 and older
    Site
    Northwestern University, Chicago, Illinois
    Locations
    52 in total
    Run by
    National Cancer Institute (NCI)

    See if you can join NCT03816345 on ClinicalTrials.gov

  2. A Master Protocol (IIBD): A Study of Multiple Drugs in Adults With Ulcerative Colitis or Crohn's Disease

    Study IIBD is a master protocol that will support a collection of individual sub studies that share key design components. Participants will be assigned to the appropriate study prior to randomization to a treatment group. The studies aim to evaluate the efficacy and safety of new treatments in adu…

    Stage
    Phase 2
    Ages
    18 to 80
    Site
    Rush University Medical Center, Chicago, Illinois
    Locations
    70 in total
    Run by
    Eli Lilly and Company

    See if you can join NCT07483073 on ClinicalTrials.gov

  3. A Study of LY4395089 and Mirikizumab (LY3074828) Given Together and Mirikizumab (Alone) in Adults With Crohn's Disease

    The main purpose of this study is to see how the safety and efficacy of a farnesoid X receptor (FXR) agonist (LY4395089), given together with mirikizumab compares with mirikizumab (alone) in adults with moderately to severely active Crohn's disease (CD). This study is part of the IIBD master protoc…

    Stage
    Phase 2
    Ages
    18 to 80
    Site
    Rush University Medical Center, Chicago, Illinois
    Locations
    70 in total
    Run by
    Eli Lilly and Company

    See if you can join NCT07483099 on ClinicalTrials.gov

  4. Treat-to-Target of Endoscopic Remission in Patients With IBD in Symptomatic Remission

    The purpose of this study is to compare the effectiveness and safety of a strategy of switching to an alternative targeted immunomodulator (TIM) therapy to treat to a target of endoscopic remission, versus continuing index TIM in patients with inflammatory bowel disease (IBD) (Crohn's disease or ul…

    Stage
    Not phased
    Ages
    18 and older
    Site
    University of Chicago Medicine, Chicago, Illinois
    Locations
    24 in total
    Run by
    Mayo Clinic

    See if you can join NCT05230173 on ClinicalTrials.gov

How to read this page. Every study here comes from ClinicalTrials.gov, the public registry that research teams are required to file with. We have summarised each one in plain language and shown where it is running. We have not changed what any study says it is doing.

What TrialBoost is. We help people find research that might suit them, and, if they ask us to, we pass their details to the research team running it. We are not a doctor, a research site, or a study sponsor, and we do not decide who takes part in anything. Joining costs nothing and you can change your mind at any point.

Paid placement. Some studies pay us when someone asks to be connected to them. Those are labelled Sponsored wherever they appear, and they only appear when they match what you were actually looking for.